{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:22:31Z","timestamp":1781230951282,"version":"3.54.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.brachy.2020.10.007","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T09:51:13Z","timestamp":1613901073000},"page":"966-975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Complications and side effects of high-dose-rate prostate brachytherapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Kevin","family":"Martell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa A.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2020.10.007_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17434440.2018.1419058","article-title":"Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives","volume":"15","author":"Dutta","year":"2018","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.brachy.2020.10.007_bib2","first-page":"235","article-title":"Radiotherapy and hormone treatment in prostate cancer","volume":"113","author":"B\u00f6hmer","year":"2016","journal-title":"Dtsch Aerzteblatt Online"},{"key":"10.1016\/j.brachy.2020.10.007_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.21037\/tau.2017.12.08","article-title":"High dose-rate brachytherapy in the treatment of prostate cancer","volume":"7","author":"Mendez","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.brachy.2020.10.007_bib4","first-page":"2015","article-title":"Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer","volume":"34","author":"Yoshida","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.brachy.2020.10.007_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.radonc.2015.09.019","article-title":"Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer","volume":"117","author":"Aluwini","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ijrobp.2007.12.026","article-title":"A phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer","volume":"72","author":"Corner","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","article-title":"High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity","volume":"110","author":"Hoskin","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib8","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ijrobp.2010.09.006","article-title":"High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial","volume":"82","author":"Barkati","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.5114\/jcb.2019.89367","article-title":"Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience","volume":"11","author":"Barnes","year":"2019","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1578.17198","article-title":"Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dos","volume":"100","author":"Morimoto","year":"2014","journal-title":"Tumori"},{"key":"10.1016\/j.brachy.2020.10.007_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.radonc.2018.03.022","article-title":"High dose rate brachytherapy for prostate cancer: a prospective toxicity evaluation of a one day schedule including two 13.5\u202fGy fractions","volume":"127","author":"Nagore","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.radonc.2020.03.033","article-title":"Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer","volume":"147","author":"Parzen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamaoncol.2017.1879","article-title":"Adverse pathologic findings for men electing immediate radical prostatectomy defining a favorable intermediate-risk group","volume":"4","author":"Patel","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.brachy.2018.06.002","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: toxicity and 6-year biochemical results","volume":"17","author":"Prada","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ijrobp.2008.02.055","article-title":"High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer","volume":"72","author":"Sato","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ijrobp.2019.02.010","article-title":"Five-Year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer","volume":"104","author":"Siddiqui","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2017.09.038","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer","volume":"126","author":"Strouthos","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5114\/jcb.2015.48838","article-title":"High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer","volume":"7","author":"Cendales","year":"2015","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-8-115","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients","volume":"8","author":"Tselis","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ijrobp.2015.05.044","article-title":"High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up","volume":"94","author":"Yoshioka","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results","volume":"85","author":"Zamboglou","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2018.07.026","article-title":"Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer","volume":"129","author":"Yamazaki","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib25","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ijrobp.2010.10.015","article-title":"High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer","volume":"81","author":"Demanes","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-9-122","article-title":"Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer","volume":"9","author":"Ghadjar","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib27","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ijrobp.2011.05.001","article-title":"High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable\/intermediate-risk prostate cancer: preliminary toxicity data","volume":"83","author":"Ghilezan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.adro.2019.04.003","article-title":"A phase 2 randomized pilot study comparing high-dose-rate brachytherapy and low-dose-rate brachytherapy as monotherapy in localized prostate cancer","volume":"4","author":"Hathout","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","article-title":"Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer","volume":"94","author":"Jawad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.brachy.2015.01.004","article-title":"High-dose-rate brachytherapy as a monotherapy for prostate cancer-Single-institution results of the extreme fractionation regimen","volume":"14","author":"Kukie\u0142ka","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-dose-rate monotherapy for localized prostate cancer: 10-year results","volume":"94","author":"Hauswald","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.brachy.2016.11.002","article-title":"High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer","volume":"16","author":"Patel","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1442-2042.2006.01243.x","article-title":"Four year clinical statistics of iridium-192 high dose rate brachytherapy","volume":"13","author":"Shigehara","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.brachy.2020.10.007_bib35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib36","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ijrobp.2011.10.055","article-title":"High-dose-rate brachytherapy and external-beam radiotherapy for hormone-na\u00efve low- and intermediate-risk prostate cancer: a 7-year experience","volume":"83","author":"Aluwini","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib37","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.brachy.2011.01.003","article-title":"Moderate dose escalation with single-fraction high-dose-rate brachytherapy boost for clinically localized intermediate- and high-risk prostate cancer: 5-year outcome of the first 100 consecutively treated patients","volume":"10","author":"\u00c1goston","year":"2011","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib38","first-page":"410","article-title":"Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer","volume":"53","author":"Soumarov\u00e1","year":"2006","journal-title":"Neoplasma"},{"key":"10.1016\/j.brachy.2020.10.007_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib40","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.ijrobp.2005.10.005","article-title":"Anatomy-based inverse optimization in high-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: comparison of incidence of acute genitourinary toxicity between anatomy-based inverse optimization","volume":"64","author":"Akimoto","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.radonc.2007.05.019","article-title":"Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I\/II study results","volume":"84","author":"Duchesne","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib42","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/jjco\/hyn056","article-title":"Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone","volume":"38","author":"Fang","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijrobp.2008.11.006","article-title":"Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy","volume":"75","author":"Ishiyama","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.urology.2004.04.015","article-title":"High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer","volume":"64","author":"Jo","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2020.10.007_bib45","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/02841860601156140","article-title":"Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up","volume":"46","author":"K\u00e4lkner","year":"2007","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.brachy.2020.10.007_bib46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jrr\/rrw003","article-title":"Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes","volume":"57","author":"Liu","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.brachy.2020.10.007_bib47","first-page":"43","article-title":"High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control","volume":"4","author":"Pellizzon","year":"2011","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.brachy.2020.10.007_bib48","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.brachy.2015.04.004","article-title":"High-dose-rate brachytherapy boost for prostate cancer: outcomes and genitourinary toxicity","volume":"14","author":"Bece","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2014.07.013","article-title":"External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer","volume":"112","author":"Boladeras","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brachy.2015.12.008","article-title":"Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: comparison of two consecutive high-dose-rate schemes","volume":"15","author":"Olarte","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib51","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/j.1464-410X.2011.10632.x","article-title":"Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience","volume":"109","author":"Prada","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2020.10.007_bib52","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clon.2017.01.042","article-title":"Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer","volume":"29","author":"Shahid","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib53","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bju.12514","article-title":"Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer","volume":"114","author":"Spratt","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2020.10.007_bib54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.radonc.2019.02.018","article-title":"Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: clinical and dosimetric predictors in a prospective cohort study","volume":"135","author":"B\u00fcchser","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib55","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.ijrobp.2011.05.025","article-title":"Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results","volume":"82","author":"Cury","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib56","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.brachy.2010.09.005","article-title":"Urethral toxicity vs. cancer control-Lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer","volume":"10","author":"Ghadjar","year":"2011","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brachy.2012.05.003","article-title":"Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer","volume":"12","author":"Kotecha","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.5114\/jcb.2016.59216","article-title":"Single-fraction high-dose-rate brachytherapy using real-time transrectal ultrasound based planning in combination with external beam radiotherapy for prostate cancer: dosimetrics and early clinical results","volume":"8","author":"Lauche","year":"2016","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2011.08.002","article-title":"External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome","volume":"82","author":"Mart\u00ednez-Monge","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib60","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.brachy.2011.07.006","article-title":"Phase I\/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate","volume":"11","author":"Myers","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib61","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1111\/ajco.12819","article-title":"Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: a single institution experience","volume":"14","author":"Ng","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib62","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2019.01.013","article-title":"Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone","volume":"18","author":"Kent","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2019.08.017","article-title":"Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: analysis of over 500 patients","volume":"141","author":"Martell","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib64","first-page":"1","article-title":"Randomised phase II feasibility trial of image-guided external beam radiotherapy with or without high dose rate brachytherapy boost in men with intermediate-risk prostate cancer (CCTG PR15\/NCT01982786)","author":"Vigneault","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2004.10.014","article-title":"Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer","volume":"74","author":"\u00c5str\u00f6m","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/jjco\/hye115","article-title":"Toxicity and health-related quality of life during and after high dose rate brachytherapy followed by external beam radiotherapy for prostate cancer","volume":"31","author":"Egawa","year":"2001","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib67","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib68","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.0004-8461.2003.01143.x","article-title":"Treatment of localized prostate cancer using a combination of high dose rate Iridium-192 brachytherapy and external beam irradiation: initial Australian experience","volume":"47","author":"Stevens","year":"2003","journal-title":"Australas Radiol"},{"key":"10.1016\/j.brachy.2020.10.007_bib69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijrobp.2011.03.041","article-title":"Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate","volume":"82","author":"Okamoto","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib70","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.brachy.2010.11.007","article-title":"Use of cone-beam imaging to correct for catheter displacement in high dose-rate prostate brachytherapy","volume":"10","author":"Holly","year":"2011","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib71","series-title":"Predicting Toxicity Caused by High-Dose-Rate Brachytherapy Boost for Prostate Cancer","author":"Estefan","year":"2019"},{"key":"10.1016\/j.brachy.2020.10.007_bib72","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2020.10.007_bib73","first-page":"8903","article-title":"Preoperative symptoms predict continence after post-radiation transurethral resection of prostate","volume":"24","author":"Polland","year":"2017","journal-title":"Can J Urol"},{"key":"10.1016\/j.brachy.2020.10.007_bib74","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy\u2019s 10-year results","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib75","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clon.2018.06.007","article-title":"Short-term toxicity of high dose rate brachytherapy in prostate cancer patients with inflammatory bowel disease","volume":"30","author":"Mohammed","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib76","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.emc.2019.07.011","article-title":"The approach to the patient with hematuria","volume":"37","author":"Willis","year":"2019","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.brachy.2020.10.007_bib77","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijrobp.2009.04.078","article-title":"A phase III randomized trial of the timing of meloxicam with iodine-125 prostate brachytherapy","volume":"77","author":"Crook","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib78","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/cncr.23905","article-title":"Randomized trial to assess the efficacy of intraoperative steroid use in decreasing acute urinary retention after transperineal radioactive iodine-125 implantation for prostate cancer","volume":"113","author":"Mierzwa","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.brachy.2020.10.007_bib79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1078155219842646","article-title":"Safety analysis of long-term phenazopyridine use for radiation cystitis","volume":"26","author":"Shore","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.brachy.2020.10.007_bib80","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0360-3016(96)00296-9","article-title":"Low risk of perioperative infection without prophylactic antibiotics for transperineal prostate brachytherapy","volume":"36","author":"Wallner","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib81","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/JU.0000000000000156","article-title":"Transperineal prostate biopsies using local anesthesia: experience with 1,287 patients. Prostate cancer detection rate, complications and patient tolerability","volume":"201","author":"Stefanova","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2020.10.007_bib82","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s10156-013-0610-0","article-title":"Assessment of antimicrobial prophylaxis to prevent perioperative infection in patients undergoing prostate brachytherapy: multicenter cohort study","volume":"19","author":"Taoka","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.brachy.2020.10.007_bib83","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/JU.0000000000000509","article-title":"Best practice statement on urologic procedures and antimicrobial prophylaxis","volume":"203","author":"Lightner","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2020.10.007_bib84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.urology.2003.09.021","article-title":"Epididymitis after prostate brachytherapy","volume":"63","author":"Hoffelt","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.brachy.2020.10.007_bib85","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.radonc.2011.08.022","article-title":"Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?","volume":"100","author":"Morton","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib86","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.brachy.2020.02.008","article-title":"A phase IB clinical trial of 15 Gy HDR brachytherapy followed by hypofractionated\/SBRT in the management of intermediate-risk prostate cancer","volume":"19","author":"Den","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.05.032","article-title":"Low dose rate brachytherapy combined with ultra-hypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: results from a prospective trial","author":"Kollmeier","year":"2020","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib88","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib89","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.radonc.2013.05.002","article-title":"GEC\/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","volume":"107","author":"Hoskin","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib90","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.brachy.2017.09.015","article-title":"Interobserver variability in rectum contouring in high-dose-rate brachytherapy for prostate cancer: a multi-institutional prospective analysis","volume":"17","author":"Chicas-Sett","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib91","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2014.06.031","article-title":"Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning","volume":"90","author":"Hathout","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib92","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.10.007_bib93","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.eururo.2019.01.046","article-title":"Management of urinary retention in patients with benign prostatic obstruction: a systematic review and meta-analysis","volume":"75","author":"Karavitakis","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2020.10.007_bib94","first-page":"1","article-title":"Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis","volume":"2018","author":"Awad","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.brachy.2020.10.007_bib95","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijrobp.2011.12.056","article-title":"Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis","volume":"84","author":"Oliai","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib96","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1464-410X.2011.10550.x","article-title":"Comparison of intravesical hyaluronic acid instillation and hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis","volume":"109","author":"Shao","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2020.10.007_bib97","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jrr\/rrs059","article-title":"Risk factors for rectal bleeding associated with I-125 brachytherapy for prostate cancer","volume":"53","author":"Harada","year":"2012","journal-title":"J Radiat Res"},{"key":"10.1016\/j.brachy.2020.10.007_bib98","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1007\/s10620-018-5163-8","article-title":"Management of radiation proctitis","volume":"63","author":"Tabaja","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.brachy.2020.10.007_bib99","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.2011.1333","article-title":"Prediction of erectile function following treatment for prostate cancer","volume":"306","author":"Alemozaffar","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2020.10.007_bib100","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.juro.2014.02.097","article-title":"Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer","volume":"192","author":"Zelefsky","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2020.10.007_bib101","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost f","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib102","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ijrobp.2005.09.002","article-title":"A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019","volume":"64","author":"Lee","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.10.007_bib103","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.brachy.2014.05.006","article-title":"Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion","volume":"13","author":"Crook","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.10.007_bib104","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.radonc.2016.02.004","article-title":"Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial","volume":"119","author":"Gomez-Iturriaga","year":"2016","journal-title":"Radiother Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472120302269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472120302269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:17:11Z","timestamp":1761531431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472120302269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":104,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1538472120302269"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2020.10.007","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications and side effects of high-dose-rate prostate brachytherapy","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}